FDA approves first generic Advair Diskus |
News and Updates
eMediNexus Coverage from: 
FDA approves first generic Advair Diskus
eMediNexus,  31 January 2019
remove_red_eye 664 Views
#Allergy and Immunology #Pharmacist #Pulmonary Medicine

0 Read Comments                

The US Food and Drug Administration has approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). Three strengths have been approved: fluticasone propionate 100 mcg/ salmeterol 50 mcg, fluticasone propionate 250 mcg/ salmeterol 50 mcg and fluticasone propionate 500 mcg/ salmeterol 50 mcg.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now